Navigation Links
Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex

tent and selective FLT3 receptor tyrosine kinase inhibitors in vitro. Symadex is currently in Phase 2 clinical trials in oncology indications. Xanthus is also exploring the use of Symadex for the treatment of a number of autoimmune diseases, where early preclinical data has shown encouraging signs of activity.

About Xanthus Pharmaceuticals, Inc.

Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule therapeutic candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise to advance its current pipeline to address significant unmet medical need in oncology and autoimmune diseases.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at www.xanthus.com.

This press release contains forward-looking statements concerning Xanthus that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Xanthus' actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether results obtained in early clinical studies or in preclinical studies such as the studies referred to above will be indicative of results obtained in future clinical trials or warrant additional trials; whether products based on Xanthus' technology will advance through the clinical trial process and receive approval from the United States Food and Drug A
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
Breaking Medicine Technology:
... THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 ... Inc. (NYSE: PFE ) today announced new ... body of evidence supporting the efficacy and safety profile ... the United States (U.S.). Eighteen abstracts across four indications, ...
... May 25, 2011 Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market its 2.25 ... in vessels as small as 2.25 mm in diameter.  The ... The PROMUS Stent features a thin-strut, open-cell design ...
Cached Medicine Technology:Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 2Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 3Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 4Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 5Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 6Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 7Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 8Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 9Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 10Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 11Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 12Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 13Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 4
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Glucosamine supplements ... and knee osteoarthritis may have an unexpected side effect: ... new study of older adults suggests. Glaucoma ... (IOP) or pressure inside the eye. Left untreated, glaucoma ... In the new study of 17 people, ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
(Date:5/23/2013)... (HealthDay News) -- People who eat at fast-food restaurants ... and teens are the worst offenders, a new study ... their meals by as much as 34 percent, parents ... and adults by as much as 20 percent," study ... release from the Robert Wood Johnson Foundation, which helped ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... May 26, 2010 Complete Genomics Inc., a third-generation ... a wholly owned member of the Roche Group (SIX: ... and analytics services to sequence and compare a patient,s ... like this allow researchers to compare the patient,s genome ...
... amounts in the gums, those tough pink tissues that hold the ... to develop an early, non-invasive test for gum disease, the No. ... quart of which people produce each day, but gingival crevicular fluid ... tooth. The study, the most comprehensive analysis of GCF to date, ...
... People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a ... and possible adverse side effects on oral health, according to ... of the American Dental Association (JADA). , Use of ... bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or ...
... ... at over 3,000 retail sites. , ... (PRWEB) May 26, 2010 -- Buckts Firefox Add-on delivers discounts and ... purchase. When a shopper visits an online retailer, clicking on the highlighted ShoppingBuckt ...
... ... $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major retailers, representing ... offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
... expected changes to oversight of supplement industry , WEDNESDAY, ... dietary herbal supplements has found trace amounts of lead, ... tested, plus myriad illegal health claims made by supplement ... , The levels of heavy metal contaminants did not ...
Cached Medicine News:Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3Health News:Many Supplements Said to Contain Toxins, Make False Health Claims 2
Bausch & Lomb SofLens59 contact lenses combine excellent performance, comfort and visual acuity providing daily wear for two week replacement....
The Prism Exophthalmometer provides precise measurement of patient's exophthalmos....
PLX40s, 40 Watt Sealed CO2 Laser System....
Both corneal topography and refractive error data are measured together in a single step to minimize alignment errors. Objective autorefractometry and autokeratometric readings of sphere, cylinder an...
Medicine Products: